SSwitzerland Read More How tragedy of son’s death led healthy mum on journey to end life at Swiss clinic2026-04-23 Wendy Duffy has flown to the Swiss clinic Pegasos clinic to end her life, unable to live with…
SSwitzerland Read More Healthy mum’s heartbreaking final acts before ending her life at Swiss clinic2026-04-23 Wendy Duffy, 56, has flown to Switzerland to end her life as she is unable to get over…
SSwitzerland Read More Brit mum with no terminal illness pays £10k to end her life at Swiss clinic2026-04-23 WARNING: SENSITIVE CONTENT Wendy Duffy, 56, is the first person to speak publicly about travelling to Switzerland for…
GGeneva Read More Psychiatry and AI: A New Era of Treatment2026-04-04 A scan showing areas of brain growth and loss of tissue for a patient with childhood-onset schizophrenia. AFP…
NNovartis Read More Novartis Shares Bolstered by Kidney Disease Therapy Milestone2026-03-29 Novartis’s Fabhalta shows 49.3% slower kidney decline in IgA nephropathy trial, securing FDA Priority Review and bolstering its…
NNovartis Read More WHO and Novartis extend partnership to eliminate leprosy for another 5 years2026-03-16 Access to treatment for leprosy is essential to global efforts to eliminate leprosy, says the World Health Organization…
NNovartis Read More Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients2026-02-26 Facility expected to be operational in 2028 in Dallas-Fort Worth area, expanding largest RLT manufacturing network in US…
NNovartis Read More Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients2026-02-26 Facility expected to be operational in 2028 in Dallas-Fort Worth area, expanding largest RLT manufacturing network in US…
RRoche Read More Roche’s Columvi combination shows sustained survival benefit at three-year follow up of pivotal phase III STARGLO study2026-02-22 F. Hoffmann-La Roche Ltd Overall survival was twice as long for people treated with Columvi in combination with…
NNovartis Read More Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)2026-02-18 Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1…